UroGenesys Inc. has developed a platform focused on finding proteins involved in urological diseases as fast as possible. In two years of work, the company has identified 40 proteins that meet strict criteria for differential expression not only in prostate cancer tissue but at specific stages of the disease.

The company uses a series of mouse models xenografted with tissues extracted from patients' primary as well as metastatic and androgen-independent tumors to fuel both its gene discovery and target validation efforts. UroGenesys believes its platform will apply equally well to cancers outside urology.